LUND, Sweden, July 8, 2025 — Hansa Biopharma AB, known as “Hansa” (NASDAQ Stockholm: HNSA), announced today the appointment of Dr. Richard Philipson as its Chief Medical Officer (CMO), effective July 14. Dr. Philipson is set to report directly to CEO Renée Aguiar-Lucander and will join the Executive Committee.

Dr. Philipson brings more than 25 years of industry experience, marked by a strong record in drug development. His clinical leadership has led to four product approvals, encompassing rare diseases and gene therapy. He is also recognized for his proficiency in forming effective teams, constructing robust pipelines, and implementing clinical development programs across all stages. Furthermore, he possesses extensive understanding of regulatory strategies in drug development. Most recently, Dr. Philipson served as CMO at Calliditas Therapeutics. Prior to that, he spent 16 years at GlaxoSmithKline (GSK), including a four-year tenure as Therapeutic Area Head within the Rare Diseases Unit. His background also includes experience at Takeda and a four-year term as CMO at Trizell.

“We are delighted to welcome Dr. Philipson to the executive management team as our new CMO. His invaluable experience in drug development, spanning from first-in-human trials to Phase 3 and post-approval studies, coupled with his expertise in rare diseases, inflammation, and oncology, will be crucial as we embark on the next stage of our growth,” stated CEO Renée Aguiar-Lucander.

Dr. Philipson commented, “I am enthusiastic about the chance to join Hansa during this pivotal phase of the company’s evolution. I anticipate collaborating with the Hansa team and applying my expertise from previous positions to facilitate upcoming regulatory filings and to formulate a strategic development blueprint for potential future indications.”

For additional information, please contact:
Evan Ballantyne, Chief Financial Officer

Stephanie Kenney, VP Global Corporate Affairs

Editorial Notes

About Hansa Biopharma

Hansa Biopharma AB stands as a groundbreaking, commercial-stage biopharmaceutical firm dedicated to creating and marketing innovative, life-saving and life-changing therapies for individuals suffering from rare immunological disorders. The company maintains an extensive and growing research and development initiative, built upon its exclusive IgG-cleaving enzyme technology platform, aiming to fulfill significant unmet medical requirements in autoimmune conditions, gene therapy, and transplantation. Its current product lineup features imlifidase, a pioneering immunoglobulin G (IgG) antibody-cleaving enzyme treatment, demonstrated to facilitate kidney transplantation for highly sensitized patients, as well as HNSA-5487, a next-generation IgG-cleaving molecule offering potential for re-dosing. Hansa Biopharma’s headquarters are located in Lund, Sweden, with operations extending across Europe and the U.S. The company’s shares are traded on Nasdaq Stockholm under the symbol HNSA. Further details can be found at and updates are available on .

©2025 Hansa Biopharma AB. Hansa Biopharma, alongside its beacon logo, IDEFIRIX, and the IDEFIRIX flower logo, are registered trademarks of Hansa Biopharma AB, based in Lund, Sweden. All rights are reserved.

This information was brought to you by Cision

The following files are available for download: